IBRX
ImmunityBioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IBRX Profile
Immunitybio, Inc.
A clinical-stage biotech company developing novel immunotherapies for cancer and infectious diseases
3530 John Hopkins Court, San Diego, California 92121
--
ImmunityBio, Inc., was incorporated on October 7, 2002 under the name of ZelleRx Corporation, Illinois, and on January 22, 2010, the company changed its name to Conkwest Co., Ltd. ImmunityBio is a leading late-stage immunotherapy company that activates the innate and adaptive immune systems to treat serious unmet needs in oncology and infectious diseases. The company is a leading manufacturer of ready-made natural killer cell therapies in clinical formulations, a comprehensive platform for memory NK cells, along with antibody cytokine fusion proteins, albumin-binding chemical immunomodulators and vaccine vectors. By combining these NK, macrophage and T-cell activation platforms, the company believes that ImmunityBio is a leader in immunotherapy with late-stage clinical development across multiple tumor types and infectious diseases.
